Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07128303 · ClinicalTrials.gov registry record · Phase 1

Study of GS-5319 in Adults With Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by Gilead Sciences.

Recruiting
Registry status
Phase 1
Development phase
178
Enrollment target
8
Study locations

NCT07128303: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Gilead Sciences.

NCT07128303 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 178 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07128303, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Gilead Sciences.

RECRUITING
Registry status
Phase 1
Development phase
178 participants
Enrollment target
8
Study locations

Study Summary

The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability in adults with solid tumors, where the participants show a specific gene alteration in the tumor. The gene helps produce methylthioadenosine phosphorylase (MTAP) enzyme. MTAP enzyme helps in normal growth of cells. The primary objectives of the study are to assess the safety and tolerability of GS-5319 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors and to identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and/or the recommended dose for expansion (RDE).

Conditions Studied

Interventions

  • DRUG GS-5319

Study Locations (8)

Other

  • Asan Medical Center - Seoul
  • Samsung Medical Center - Seoul
  • Vall d'Hebron Institute of Oncology (VHIO) - Barcelona
  • START Madrid - FJD - Hospital Fundación Jiménez Díaz - Phase I Clinical Trials Unit - Madrid
  • START - Centro Oncológico Clara Campal - Madrid

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Texas

  • START San Antonio - San Antonio

Virginia

  • NEXT Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 178 participants
Start Date 2025-08-28
Est. Completion 2028-05
Phase Phase 1
Gilead Sciences

504 total trials

What NCT07128303 shows while recruiting

NCT07128303 is an interventional study that assigns participants to a tested intervention. The registered 178 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which GS-5319 is the first listed.

NCT07128303 lists 8 locations in 4 states (Other, Massachusetts, Texas).

Frequently Asked Questions

What is clinical trial NCT07128303 about?

NCT07128303 is a clinical study titled "Study of GS-5319 in Adults With Solid Tumors". The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability in adults with solid tumors, where the participants show a specific gene alteration in the tumor. The gene helps produce methylthioadenosine phosphorylase (MTAP) enzyme. MTAP enzyme he...

What is the current status of trial NCT07128303?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 178 participants. The study started on 2025-08-28. Estimated completion is 2028-05.

What conditions does trial NCT07128303 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT07128303?

The interventions under investigation include: GS-5319 (DRUG).

Who is sponsoring clinical trial NCT07128303?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07128303 being conducted?

This trial has 8 study locations across Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07128303's enrollment target sits among peer trials

178 72nd of 189 higher than 118 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03642002 · 178 participants · NA

    The Effects of Music Therapy on Adult Patients Requiring Mechanical Ventilation in the ICU

  • NCT04227847 · 178 participants · Phase 1

    A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

  • NCT04855214 · 178 participants

    Evaluating the Experience of Upper Limb Prosthesis Use

  • NCT05391126 · 178 participants · NA

    GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07128303, the US trial registry maintained by the National Library of Medicine. NCT07128303 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.